Similar articles

• [Serum thyroxine and triiodothyronine levels after a single dose and after 2-month-long thiamazole treatment of Graves' disease with reference to drug's pharmacokinetics].

  Syrenicz A. Syrenicz A. Ann Acad Med Stetin. 1990;36:133-52. Ann Acad Med Stetin. 1990. PMID: 2099104 Polish.
• [What is the recurrence rate for Basedow's disease treated with thyrostatic agents. Answers from a prospective study].

  Schleusener H, Peters H, Fischer C, Holle R, Bogner U, Reinwein D, Benker G. Schleusener H, et al. Schweiz Med Wochenschr. 1990 May 26;120(21):769-71. Schweiz Med Wochenschr. 1990. PMID: 2349460 German.
• Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.

  Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L. Bojarska-Szmygin A, et al. Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):248-53. Ann Univ Mariae Curie Sklodowska Med. 2003. PMID: 15314994 Clinical Trial.
• Remission of Graves' hyperthyroidism treated with methimazole.

  Bolaños F, González-Ortiz M, Durón H, Sánchez C. Bolaños F, et al. Rev Invest Clin. 2002 Jul-Aug;54(4):307-10. Rev Invest Clin. 2002. PMID: 12415954 Review.
• [The transformation of Basedow's struma into nodular goiter: a reason for recurrence of hyperthyroidism].

  Studer H, Huber G, Derwahl M, Frey P. Studer H, et al. Schweiz Med Wochenschr. 1989 Feb 18;119(7):203-8. Schweiz Med Wochenschr. 1989. PMID: 2652283 Review. German.